Search
Odesivimab
go.drugbank.com/drugs/DB15900ApprovedInvestigationalINMAZEB™ is produced by Regeneron Pharmaceuticals and was granted FDA approval on October 14, 2020.[L17320] … [A222078] INMAZEB™, formerly referred to as REGN-EB3, combines the three humanized IgG1κ mAbs Odesivimab (REGN 3471), [Maftivimab] (REGN 3479), and [Atoltivimab] (REGN 3470) in equimolar proportions
Oxymetazoline
go.drugbank.com/drugs/DB00935ApprovedInvestigational[L15062] As an effective decongestant, oxymetazoline is available in over-the-counter intranasal sprays used to relieve nasal and sinus congestion caused by a wide variety of conditions, such as common
Categories: Sympathomimetics Used as DecongestantsBenzethonium
go.drugbank.com/drugs/DB11125ApprovedBenzethonium was identified as a novel cancer-specific compound by cell-based small-molecule screen [A32298]. … It is additionally found in cosmetics and toiletries such as mouthwashes and anti-itch ointments.
Calaspargase pegol
go.drugbank.com/drugs/DB14730ApprovedInvestigationalCalaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL [L4890]. … Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) [L4890].
Biperiden
go.drugbank.com/drugs/DB00810ApprovedInvestigationalWithdrawnA muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. … It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.
Clenbuterol
go.drugbank.com/drugs/DB01407ApprovedInvestigationalVet approvedA substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
Amikacin
go.drugbank.com/drugs/DB00479ApprovedInvestigationalVet approved[A39531] Amikacin's unique property is that it exerts activity against more resistant gram-negative bacilli such as Acinetobacter baumanii and Pseudomonas aeruginosa. … [F1949] In September 2018, a liposomal inhalation suspension of this drug was approved by the FDA for the treatment of lung disease caused by Mycobacterium avium complex (MAC) bacteria in a small population
Lenalidomide
go.drugbank.com/drugs/DB00480ApprovedInvestigational[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that … Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties.
Spironolactone
go.drugbank.com/drugs/DB00421ApprovedInvestigational[A178135, A261025] Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.[A178243] … [A11837] Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered.
Pretomanid
go.drugbank.com/drugs/DB05154ApprovedInvestigationalIt was the first TB drug developed by a nonprofit organization, known as TB Alliance, and was granted FDA approval on August 14, 2019. … Research in recent years has been geared toward the development of novel therapies that target persistent forms of this disease, which have shown resistance to standard therapy regimens.